Indeed, we tested the diagnostic and prognostic values of miRNAs reflecting the features of gliomas (IDH mutation, microvascular proliferation, hypoxia) and patients’ survival in a series of 97 gliomas of grades II to IV to determine whether miRNAs could be used as tools for monitoring patients with gliomas. The gene discussed is IDH2; the disease is central nervous system cancer.